Cubist Cubicin S. aureus sNDA
This article was originally published in Pharmaceutical Approvals Monthly
Cubist is requesting a priority review for its Cubicin (daptomycin) sNDA filing for treatment of endocarditis and bacteremia caused by Staphylococcus aureus, the firm says Sept. 26. Cubist previously expressed confidence that its pivotal trial supports a broad label. Cubicin showed higher success rates than comparator therapy in the Phase III trial, although those rates did not reach statistical significance (1Pharmaceutical Approvals Monthly July 2005, p. 5). The data will be presented for the first time at the Interscience Conference on Antimicrobial Agents and Chemotherapy Dec. 16-19 in Washington, D.C...
You may also be interested in...
Cubist plans to request a priority review for an sNDA it will submit by year-end for use of its Cubicin antibiotic for endocarditis and bacteremia
Arena's Phase IIb CAPTIVATE trial assessing investigational olorinab in IBS missed its primary endpoint.
More Encouraging Real World Data From UK – But Can It Turn Around European Sentiment On AZ COVID-19 Vaccine?
Another real-world study from the UK’s rapid vaccine rollout provides evidence that Pfizer’s vaccine saves lives, with the AZ shot matching it on cutting hospitalizations.